Uncovering the molecular drivers of B-cell lymphoma tumor growth
Northwestern Medicine scientists have uncovered a key pathway controlling tumor growth in B-cell lymphomas, according to a ...
Doctors enroll patients in trial for aggressive blood cancer
Doctors are enrolling patients in a groundbreaking clinical trial aimed at reducing cancer recurrence in patients with ...
Marker Therapeutics initiated with a Buy at Brookline
Brookline initiated coverage of Marker Therapeutics (MRKR) with a Buy rating and $4 price target Marker is a clinical-stage immuno-oncology ...
Brookline Capital sets $4 target on Marker Therapeutics stock
Brookline Capital Markets initiated coverage on Marker Therapeutics (NASDAQ:MRKR), a company focused on developing T cell-based immunotherapies for cancer, with a Buy rating and a 12-to-18-month price ...
MRKR stock touches 52-week low at $1.61 amid market challenges
In a challenging market environment, Marker Therapeutics Inc. (NASDAQ:MRKR) stock has reached a 52-week low, dipping to $1.61. According to InvestingPro analysis, the stock appears undervalued at ...
The American Journal of Managed Care5d
Refining Remission Assessment in Aggressive B-Cell Lymphomas
Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, ...
The American Journal of Managed Care13d
Study Expands Knowledge of Prognostic Markers in Extranodal NHL
Extranodal non-Hodgkin lymphoma (NHL) makes up over one-third of NHL cases, yet remains understudied and in need of deeper ...
Medscape1d
Helicobacter Pylori: Phenotypes, Genotypes and Virulence Genes
gastric adenocarcinoma and gastric B-cell lymphoma. Various bacterial virulence factors are associated with the development of such gastric diseases, and the characterization of these markers ...